Sarepta Therapeutics (SRPT) August 25, 2025 Lead Plaintiff Deadline Approaching, SRPT Investors with Substantial Losses Encouraged to Contact Hagens Berman

SAN FRANCISCO, Aug. 18, 2025 (GLOBE NEWSWIRE) -- The pending securities class action was triggered after news of safety problems with Sarepta’s (NASDAQ: SRPT) ELEVIDYS, a medication intended for the treatment of Duchenne muscular dystrophy. The deadline for Sarepta investors with losses who wish to be considered by the court to serve as Lead Plaintiff is August 25, 2025. Accordingly, national shareholders rights firm Hagens Berman urges Sarepta investors who suffered substantial losses to submit your losses ...